DHT (Dihydrotestosterone): Hair, Prostate, Sexual Health, and Testosterone Metabolism
Dihydrotestosterone, better known as DHT, is made when the enzyme 5-alpha-reductase converts testosterone into a more potent androgen. The conversion takes place largely within tissues, particularly the prostate, skin, scalp, and genital tissues. Once testosterone becomes DHT, it cannot be converted into estradiol.
DHT is central to the biology of male-pattern hair loss and prostate growth, which is why medications such as finasteride and dutasteride work by reducing its production. That does not make DHT an inherently harmful hormone. It has important roles in male sexual development and androgen signaling, and lowering it can produce unwanted effects in some people.
A serum DHT result also has limitations. The amount of DHT circulating in the blood does not necessarily tell us how much is being produced or used inside an androgen-sensitive tissue. For most adults, DHT is therefore not a stand-alone longevity marker or a number that needs to be optimized. It becomes useful when there is a clinical reason to understand 5-alpha-reductase activity, hair loss, prostate treatment, medication effects, or an unusual androgen pattern.
In This Article
What DHT Is | Testosterone vs. DHT | Where DHT Acts | DHT and Hair Loss | DHT and the Prostate | Sexual Function | Finasteride and Dutasteride | Testosterone Therapy | DHT Testing | FAQ
DHT has acquired an unusually dramatic reputation for a hormone most people never have measured.
Hair-loss advertising often presents it as the hormone attacking the scalp. Prostate discussions associate it with enlargement. Men taking testosterone sometimes become concerned when their DHT rises. At the other extreme, DHT is occasionally marketed as though it were a better or more masculine version of testosterone.
Neither description is particularly helpful.
Dihydrotestosterone is a normal metabolite of testosterone. In tissues that contain the enzyme 5-alpha-reductase, testosterone can be converted into DHT before it reaches the androgen receptor. DHT then binds that receptor more avidly and produces a stronger androgenic signal than testosterone can produce at the same concentration.
The important part is where this happens.
DHT is especially relevant in the prostate, skin, sebaceous glands, scalp hair follicles, and external genital tissues. Testosterone has major effects elsewhere without needing to become DHT. Testosterone can also take an entirely different route and become estradiol through aromatase.
The body is not choosing between three competing hormones. Testosterone, DHT, and estradiol are three parts of the same steroid-hormone physiology, with different enzymes determining which signal predominates in a given tissue.
For the larger framework, see the Hormone Optimization and Longevity Medicine Hub.
What Is DHT?
DHT, or dihydrotestosterone, is produced when 5-alpha-reductase modifies testosterone. The reaction is essentially a one-way street. Once testosterone has been converted to DHT, DHT cannot be aromatized into estradiol.
There are two principal 5-alpha-reductase enzymes involved in androgen physiology, usually referred to as type 1 and type 2. Their distribution differs across tissues.
Type 2 activity is particularly important in the prostate and genital tissues. Type 1 is found prominently in skin and several other tissues. The distribution is one reason DHT biology is so local. Testosterone circulating through the bloodstream may encounter very different enzymatic environments depending on where it goes.
DHT and testosterone ultimately activate the same androgen receptor, but they do not activate it identically. DHT binds more strongly and remains associated with the receptor longer. The resulting signal can therefore be considerably more potent in tissues equipped to produce DHT.
This local conversion is sometimes described as androgen amplification, which is a useful way to think about it. The tissue takes testosterone and turns up the androgen signal before the receptor is activated.
Testosterone and DHT Are Not Interchangeable
Calling DHT “strong testosterone” misses how differently the two hormones are used.
Testosterone is the major circulating androgen in adult men. It supports muscle, bone, sexual physiology, erythropoiesis, reproductive function, and numerous other processes. It can bind the androgen receptor directly, become DHT through 5-alpha-reductase, or become estradiol through aromatase.
DHT has a narrower metabolic future. It is a powerful androgen, but it cannot become estradiol.
This difference helps explain something that initially seems surprising: reducing DHT does not necessarily erase the major anabolic effects of testosterone.
Men with congenital deficiency of type 2 5-alpha-reductase provide an unusual natural experiment. DHT-dependent sexual development is markedly altered, yet testosterone can still support substantial muscle development, bone health, spermatogenesis, and many other androgen-dependent functions after puberty.
DHT is therefore essential for certain androgen effects and much less important for others.
That is more useful than calling it simply stronger.
DHT Is Primarily a Tissue Story
One of the easiest mistakes to make with DHT is assuming that the concentration in a blood sample represents the androgen environment inside the scalp or prostate.
It does not necessarily do that.
A meaningful amount of DHT is created locally within androgen-sensitive tissues and can act there before being metabolized further. Local 5-alpha-reductase activity, androgen receptor expression, genetics, age, and tissue biology can all influence the response.
This explains why two men with similar serum testosterone and DHT concentrations may have completely different experiences with scalp hair.
One may retain a full head of hair into old age. The other may develop androgenetic alopecia in his twenties.
The difference is not simply how much androgen is circulating in their blood. The follicles themselves are different.
The same principle applies to prostate tissue. Serum DHT provides information about circulation, but it cannot be treated as a direct measurement of intraprostatic androgen activity.
DHT and Male-Pattern Hair Loss
The connection between DHT and androgenetic alopecia is real, but it needs one important qualifier: susceptibility.
In genetically susceptible scalp follicles, androgen signaling contributes to progressive follicular miniaturization. The growing phase of the hair cycle becomes shorter, the follicle becomes smaller, and the hair produced becomes progressively finer until scalp coverage is visibly reduced.
DHT is particularly important because the affected follicles have the machinery to convert testosterone through 5-alpha-reductase and respond to androgen signaling.
This is why lowering DHT can slow hair loss and improve hair growth in many men.
It is also why measuring serum DHT usually adds surprisingly little to the diagnosis of ordinary male-pattern baldness. A man does not need an abnormally high blood DHT level to develop androgenetic alopecia. Normal androgen concentrations can produce hair loss when the follicles are genetically susceptible.
The opposite is equally true. A high-normal DHT result does not mean someone is destined to lose his hair.
The scalp matters at least as much as the bloodstream.
DHT and the Prostate
The prostate is another tissue where 5-alpha-reduction matters considerably.
Testosterone enters prostate cells and is converted to DHT, creating a strong local androgen signal. DHT contributes to normal prostate development and helps maintain androgen-dependent prostate tissue throughout adult life.
With aging, benign prostate enlargement becomes increasingly common. DHT is involved in this biology, which is why reducing DHT can shrink an enlarged prostate and reduce the risk of urinary retention or the need for surgery in appropriately selected men.
That observation is sometimes turned into the much broader statement that DHT causes prostate disease.
Prostate biology is considerably more complicated.
Age, genetics, stromal and epithelial signaling, inflammation, metabolic factors, sex steroids, growth factors, and other processes participate in benign prostatic hyperplasia. DHT is important enough that blocking its production can be therapeutic, but it is not a complete explanation for why one man develops substantial BPH and another does not.
The same caution applies to prostate cancer. Androgen signaling is fundamental to prostate cancer biology, but a serum DHT concentration cannot be used as a prostate-cancer risk score.
Men with urinary symptoms still need a conventional urologic evaluation rather than an attempt to diagnose the prostate from a hormone panel.
DHT and Sexual Function
The sexual effects of DHT are harder to isolate than its effects in scalp hair or prostate tissue.
Testosterone, estradiol, nitric oxide signaling, vascular health, neurological function, medications, sleep, metabolic health, relationship factors, and psychological health can all affect libido and erectile function. DHT sits inside that much larger system.
We know that some men taking medications that substantially reduce DHT report decreased libido, erectile difficulty, or ejaculatory changes. Many men take the same medications without noticeable sexual side effects.
That difference is clinically important.
It tells us that lowering DHT is not physiologically neutral, but it also does not establish a simple DHT threshold below which sexual function fails.
A man who develops sexual symptoms after beginning a 5-alpha-reductase inhibitor deserves to have the timing taken seriously. He also deserves a broader evaluation rather than assuming every change in sexual function has one hormonal explanation.
Finasteride and Dutasteride: What They Actually Do
Finasteride and dutasteride reduce DHT by inhibiting 5-alpha-reductase.
Finasteride primarily inhibits the type 2 enzyme. Dutasteride inhibits both type 1 and type 2 and therefore produces more extensive suppression of circulating DHT.
That pharmacology has legitimate clinical uses.
Finasteride is FDA approved for male-pattern hair loss and, at a different dose, benign prostatic hyperplasia. Dutasteride is FDA approved for BPH and is also used for androgenetic alopecia in some settings, although its regulatory status for hair loss varies by country and indication.
For a man with a substantially enlarged prostate, reducing intraprostatic DHT can shrink prostate volume and reduce the likelihood of disease progression. For a man losing genetically susceptible scalp hair, reducing follicular androgen signaling can help preserve hair.
Those benefits have to be considered alongside potential adverse effects. Sexual side effects occur in a minority of users. Fertility considerations may matter in some men. Mood or other symptoms warrant individual assessment rather than dismissal.
There is another practical issue that should never be overlooked: 5-alpha-reductase inhibitors lower PSA.
A clinician interpreting prostate-specific antigen needs to know that a patient is taking finasteride or dutasteride. A PSA value obtained during treatment cannot simply be interpreted as though the medication were absent.
What About “Post-Finasteride Syndrome”?
Persistent symptoms reported after finasteride use have generated years of debate.
Some former users report sexual, neurological, or psychological symptoms that continue after the medication has been discontinued. These experiences should not be dismissed simply because the mechanism remains uncertain.
At the same time, the literature has not established a single well-defined biological mechanism that explains every persistent symptom attributed to finasteride, and determining incidence and causation has been difficult.
That leaves clinicians with a less satisfying but more responsible position: discuss potential adverse effects before treatment, take new symptoms seriously if they appear, and avoid pretending that either absolute certainty or absolute impossibility has been established where it has not.
DHT During Testosterone Therapy
Testosterone therapy can increase DHT because more testosterone becomes available for 5-alpha-reduction.
The amount of change depends partly on the formulation. Testosterone delivered through the skin can produce relatively prominent DHT increases because skin contains 5-alpha-reductase. Other delivery methods create different pharmacokinetic patterns.
An increase in serum DHT during testosterone treatment is not automatically evidence that the dose is dangerous.
It also does not mean the result should be ignored if the patient develops new scalp hair loss, acne, prostate symptoms, or another androgen-sensitive problem.
The hormone result has to be read beside the treatment.
If testosterone itself is being driven to unnecessarily high concentrations, reducing the testosterone exposure may make considerably more sense than adding another medication to block one of its metabolites.
This is a recurring theme in hormone medicine. More drugs are not always the answer to the effects of too much drug.
For more on treatment itself, see Testosterone Therapy for Men Over 40.
Does DHT Matter for Muscle and Bone?
DHT is a potent androgen, but it should not be mistaken for the principal driver of every androgen-dependent tissue.
Skeletal muscle responds strongly to testosterone itself. Bone benefits from testosterone and from estradiol produced through aromatization. DHT is not aromatizable and does not appear to be required for the major musculoskeletal effects commonly associated with testosterone.
This is one reason blocking 5-alpha-reductase does not simply reproduce the physiology of severe testosterone deficiency.
The distinction matters in longevity medicine because muscle and bone are major determinants of healthspan. Measuring DHT does not provide a shortcut to evaluating either one.
Muscle is better evaluated with strength, function, lean mass, nutrition, and physical activity. Bone is better evaluated with fracture history, risk factors, and DEXA when appropriate.
DHT in Women
DHT is present in women too, although concentrations are substantially lower than in men.
Women produce androgen precursors in the ovaries and adrenal glands, and local tissues can generate DHT through 5-alpha-reductase. When androgen signaling becomes excessive, DHT-related pathways can contribute to acne, increased facial or body hair, and androgen-sensitive scalp hair loss.
As in men, serum measurements do not tell the entire story. Hair follicles and sebaceous glands respond according to local enzyme activity and androgen sensitivity.
A woman with androgenic symptoms therefore needs an endocrine evaluation that considers testosterone, free testosterone, SHBG, DHEA-S, clinical history, medications, ovarian physiology, and other possible causes rather than assuming the problem is simply a high DHT level.
When Is Measuring DHT Useful?
DHT is not a routine longevity laboratory test.
For most adults without a specific androgen-related question, measuring it adds little to a well-constructed hormone assessment.
There are situations where it can help. An unusual testosterone-metabolism pattern, suspected disorders of 5-alpha-reductase activity, selected cases involving testosterone therapy, or questions about the biochemical effect of a 5-alpha-reductase inhibitor may justify testing.
Even then, the result has to be interpreted carefully because serum DHT is not a biopsy of the scalp or prostate.
A typical androgen evaluation may be far more dependent on total testosterone, free testosterone, SHBG, estradiol, symptoms, medications, and the reason the testing was ordered.
Our related articles on Free Testosterone and Longevity, Free vs. Total Testosterone, and SHBG and Longevity explain those relationships in more detail.
DHT Is Not a Longevity Target
DHT belongs in longevity medicine for the same reason many other hormones do: aging changes the tissues influenced by those hormones, medications alter their signaling, and treatment decisions can have consequences years later.
That does not make DHT a longevity biomarker.
There is no established DHT concentration that predicts a longer life, healthier aging, better cardiovascular health, greater muscle preservation, or superior sexual function.
Trying to maximize DHT because it is a potent androgen makes little sense. Trying to eliminate it because it contributes to hair loss or prostate growth makes equally little sense outside a clinical indication.
A man trying to preserve his hair may reasonably choose to reduce DHT. A man with an enlarged prostate may benefit substantially from doing the same. Another man may have no reason to interfere with the pathway at all.
The treatment belongs to the problem.
DHT is useful when it helps us understand that problem. It does not need to become one more hormone number that everyone is encouraged to chase.
Explore the Full Hormone Optimization System
DHT is one branch of testosterone metabolism. Testosterone can also act directly or be converted to estradiol, while SHBG influences the circulating hormone environment. Those relationships make more sense when they are considered together.
Related Longevity Medicine Resources
FAQ: DHT, Testosterone, Hair, and Prostate Health
What is DHT?
DHT, or dihydrotestosterone, is a potent androgen produced when the enzyme 5-alpha-reductase converts testosterone into DHT. It is particularly important in androgen-sensitive tissues such as the prostate, skin, scalp hair follicles, and external genital tissues.
Is DHT stronger than testosterone?
DHT binds the androgen receptor more strongly and can produce more potent androgen signaling at the receptor. That does not make DHT more important than testosterone in every tissue. Muscle and many other tissues respond substantially to testosterone without requiring conversion to DHT.
Does high DHT cause hair loss?
DHT contributes to androgenetic alopecia in genetically susceptible hair follicles, but a high serum DHT level is not required for male-pattern baldness. Local follicular androgen sensitivity and 5-alpha-reductase activity are important parts of the condition.
Does DHT cause an enlarged prostate?
DHT contributes to prostate growth and is an important androgen within prostate tissue. Benign prostatic hyperplasia is nevertheless influenced by aging, genetics, tissue signaling, metabolic factors, and other processes in addition to DHT.
What do finasteride and dutasteride do?
Both medications inhibit 5-alpha-reductase and reduce production of DHT. Finasteride primarily inhibits type 2 5-alpha-reductase, while dutasteride inhibits both type 1 and type 2. They are used clinically for conditions in which reducing DHT has a therapeutic benefit.
Can finasteride affect sexual function?
Yes. Decreased libido, erectile difficulty, and ejaculatory changes occur in a minority of men using 5-alpha-reductase inhibitors. Many men take these medications without experiencing sexual side effects.
Does finasteride affect PSA?
Yes. Finasteride and dutasteride can substantially lower PSA. Clinicians interpreting PSA results need to know when a patient is taking a 5-alpha-reductase inhibitor so the result can be interpreted appropriately.
Does testosterone therapy increase DHT?
It can. Increasing testosterone provides more substrate for 5-alpha-reductase, and some testosterone formulations may produce larger increases in DHT than others. A rise in serum DHT during appropriately managed testosterone therapy does not automatically require treatment.
Should DHT be routinely measured during testosterone therapy?
Not necessarily. DHT testing can be useful when there is a specific clinical reason, but total testosterone, free testosterone, SHBG, estradiol, symptoms, treatment response, and safety monitoring are generally more important parts of testosterone management.
Is there an optimal DHT level for longevity?
No established DHT concentration has been shown to optimize longevity or healthspan. DHT is best measured and interpreted when there is a specific clinical question rather than treated as a universal longevity target.
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.
Return to the Longevity Medicine Guide →